123 related articles for article (PubMed ID: 38834171)
1. Cardiovascular risk in anti-VEGF treatment of neovascular age-related macular degeneration.
Chong DD; Maatouk CM; Markle J; Shaia JK; Singh RP; Talcott KE
Can J Ophthalmol; 2024 Jun; ():. PubMed ID: 38834171
[TBL] [Abstract][Full Text] [Related]
2. Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration.
Dalvin LA; Starr MR; AbouChehade JE; Damento GM; Garcia M; Shah SM; Hodge DO; Meissner I; Bakri SJ; Iezzi R
JAMA Ophthalmol; 2019 May; 137(5):483-490. PubMed ID: 30703203
[TBL] [Abstract][Full Text] [Related]
3. Increased mortality after intravitreal injections of anti-VEGF for neovascular AMD among patients with prior stroke or acute myocardial infarction.
Chen YY; Lai YJ; Yen YF; Chou P
Eye (Lond); 2022 Jan; 36(1):153-159. PubMed ID: 33654317
[TBL] [Abstract][Full Text] [Related]
4. Risks of newly onset hemorrhagic stroke in patients with neovascular age-related macular degeneration.
Lee WA; Cheng CL; Lee CH; Kao Yang YH; Lin SJ; Hsieh CY
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1277-1285. PubMed ID: 28856767
[TBL] [Abstract][Full Text] [Related]
5. Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients.
Rahman W; Chen FK; Yeoh J; da Cruz L
Graefes Arch Clin Exp Ophthalmol; 2013 Jun; 251(6):1483-8. PubMed ID: 23160538
[TBL] [Abstract][Full Text] [Related]
6. Glaucoma progression in patients receiving intravitreal anti-VEGF treatment for neovascular age-related macular degeneration.
Pirinen I; Leinonen S; Helminen M; Hujanen P; Vaajanen A; Tuulonen A; Uusitalo-Järvinen H
Acta Ophthalmol; 2023 May; 101(3):261-265. PubMed ID: 36398433
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of Vision Needed to Drive after Intravitreal Anti-VEGF Therapy in Patients with Neovascular Age-related Macular Degeneration and Diabetic Macular Edema.
Emami-Naeini P; Garmo V; Boucher N; Fernando R; Menezes A
Ophthalmol Retina; 2024 Apr; 8(4):388-398. PubMed ID: 37866681
[TBL] [Abstract][Full Text] [Related]
8. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
9. Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.
Ciulla TA; Hussain RM; Taraborelli D; Pollack JS; Williams DF
Ophthalmol Retina; 2022 Sep; 6(9):796-806. PubMed ID: 35381391
[TBL] [Abstract][Full Text] [Related]
10. Peripapillary and macular microvasculature in neovascular age-related macular degeneration in long-term and recently started anti-VEGF therapy versus healthy controls.
Türksever C; Hoffmann L; Hatz K
Front Med (Lausanne); 2022; 9():1080052. PubMed ID: 36698793
[TBL] [Abstract][Full Text] [Related]
11. Levodopa Positively Affects Neovascular Age-Related Macular Degeneration.
Figueroa AG; Boyd BM; Christensen CA; Javid CG; McKay BS; Fagan TC; Snyder RW
Am J Med; 2021 Jan; 134(1):122-128.e3. PubMed ID: 32628915
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018: The LANDSCAPE Study.
Creuzot-Garcher CP; Srour M; Baudin F; Daien V; Dot C; Nghiem-Buffet S; Girmens JF; Coulombel N; Ponthieux A; Delcourt C
Ophthalmol Sci; 2022 Mar; 2(1):100114. PubMed ID: 36246186
[TBL] [Abstract][Full Text] [Related]
13. Risk, Prevalence, and Progression of Glaucoma in Eyes With Age-Related Macular Degeneration Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Shah SM; Boopathiraj N; Starr MR; Dalvin LA; AbouChehade J; Damento G; Garcia MD; Hodge DO; Bakri SJ; Sit AJ; Iezzi R
Am J Ophthalmol; 2022 Nov; 243():98-108. PubMed ID: 35932820
[TBL] [Abstract][Full Text] [Related]
14. Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis.
Jeon HL; Lee H; Yoon D; Lee Y; Kim JH; Jee D; Shin JY
BMJ Open; 2020 Dec; 10(12):e042484. PubMed ID: 33376178
[TBL] [Abstract][Full Text] [Related]
15. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
[TBL] [Abstract][Full Text] [Related]
16. [Neovascular recurrences in 42 treatment-naive eyes with neovascular age-related macular degeneration (AMD) followed for over 2 years].
Bodénès F; Massé H; Lebreton O; Weber M
J Fr Ophtalmol; 2021 May; 44(5):626-631. PubMed ID: 33840491
[TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF Treatment Strategies for 3 Subtypes of Neovascular Age-Related Macular Degeneration in a Clinical Setting: A Multicenter Cohort Study in Japan.
Yoneda K; Takeuchi M; Yasukawa T; Terasaki H; Yamamoto Y; Jujo T; Wakuta M; Matsubara H; Mitamura Y; Kato A; Kondo M; Kimura K; Takagi H; Gomi F; Sakamoto T;
Ophthalmol Retina; 2023 Oct; 7(10):869-878. PubMed ID: 37295608
[TBL] [Abstract][Full Text] [Related]
18. Introducing Anti-Vascular Endothelial Growth Factor Therapies for AMD Did Not Raise Risk of Myocardial Infarction, Stroke, and Death.
Yashkin AP; Hahn P; Sloan FA
Ophthalmology; 2016 Oct; 123(10):2225-31. PubMed ID: 27523614
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis.
Almony A; Keyloun KR; Shah-Manek B; Multani JK; McGuiness CB; Chen CC; Campbell JH
J Manag Care Spec Pharm; 2021 Sep; 27(9):1260-1272. PubMed ID: 34464210
[No Abstract] [Full Text] [Related]
20. Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration in Vulnerable Fellow Eyes: A Randomized Clinical Trial.
Chan CK; Lalezary M; Abraham P; Elman M; Beaulieu WT; Lin SG; Khurana RN; Bansal AS; Wieland MR; Palmer JD; Chang LK; Lujan BJ; Yiu G;
Ophthalmol Retina; 2022 Jun; 6(6):484-494. PubMed ID: 35121216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
